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Abstract
Purpose
This study investigated the significance of change in neutrophil-to-lymphocyte ratio (NLR)
during preoperative chemoradiotherapy (preop-CRT) in patients with non-metastatic rectal
cancer using a propensity score matching method (PSM).
Methods
Patients who underwent surgery after completion of preop-CRT for non-metastatic rectal
cancers from Jan 2004 to Dec 2013 were retrospectively enrolled. NLRs were obtained
before commencement of CRT (pre-NLR) and between completion of CRT and surgery
(post-NLR). Using Cox regression hazards models, the association of NLRs with survival
after PSM was examined.
Results
A total of 131 patients were grouped as follows: group A, pre-NLR < 3 & post-NLR < 3 (n =
47); group B, pre-NLR < 3 & post-NLR � 3 (n = 45); group C, pre-NLR � 3 & post-NLR < 3
(n = 5); group D, pre-NLR � 3 & post-NLR � 3 (n = 34). There was no difference in dis-
ease-free survival (DFS) or overall survival (OS) rate according to group. When dichoto-
mized into group A versus groups B-D, DFS was higher in group A (84.7%) than groups B-
D (67.5%, p = 0.021). After PSM (n = 94), multivariable analysis identified persistent lower
NLR as an independent favorable prognosticator of DFS (HR 0.37, 95% CI 0.15–0.92,
p = 0.033).
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Conclusions
Persistent non-inflammatory state measured by NLR may be an indicator of decreased risk
of recurrence in patients with locally advanced rectal cancer treated with preop-CRT.
Introduction
Colorectal cancer is a major cause of cancer-related death worldwide and in South Korea.[1–
3] Among them, nearly 30% of patients had been diagnosed with rectal cancer.[2] According
to guidelines, standard care for locally advanced rectal cancer (clinical stage II and III) is
preoperative chemoradiotherapy (preop-CRT) followed by total mesorectal excision.[4,5]
Although preop-CRT may decrease local recurrence rate in comparison to postoperative adju-
vant chemoradiotherapy, it does not improve overall survival (OS).[4,5] Risk stratification for
high risk patients to designate proper management is important to improve prognostic out-
comes in these patients.
Various markers reflecting systemic inflammatory response, such as neutrophil-to-lympho-
cyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR),
C-reactive protein (CRP), and the modified Glasgow prognostic score (mGPS), are demon-
strated prognostic factors for survival in primary operable cancers.[6] Although albumin or
CRP are not usually assessed as part of the preoperative workup for cancer patients, differential
white cell count is routinely performed to identify patients with hypercoagulability or infection
risk.[6] Among these laboratory markers, NLR is one of the most commonly used biomarkers.
It was reported that tumor affected the hematopoietic progenitor cell of the host and thus mye-
loid lineage populations (including neutrophils) could expand.[7] These myeloid-derived
suppressor cells (MDSCs) suppress host immune cells through various pathways and could
diminish lymphocytes.[8] NLR could be used to estimate the relative balance of myeloid and
lymphocytic lineages, thus reflecting host immunity in cancer patients.[8] The prognostic
impact of NLR was thoroughly investigated in different types of diseases including gastric can-
cer, hepatocellular cancer, pancreatic cancer, head and neck cancer, esophageal cancer, breast
cancer, and thyroid cancer.[9–15] In accordance with these results, previous studies including
a meta-analysis demonstrated that NLR can predict survival outcome,[16–22] or can also pre-
dict tumor regression grade, such as pathologic complete response (pCR), or good tumor
response after preop-CRT in patients with rectal cancer.[18,20,23–25]
Nevertheless, there are also a number of studies that have shown that NLR is not relevant in
patients with rectal cancer. Lino-Silva and colleagues reported that there were no differences
in survival outcomes or pCR rate according to NLR cut-off point (2.0, 2.5, 4, and 5) in 175
patients who underwent preop-CRT.[26] Shen and colleagues also reported that NLR mea-
sured in pre-CRT did not predict OS or disease-free survival (DFS) in patients with locally
advanced rectal cancer who underwent preop-CRT.[27] Jung et al. reported that NLR mea-
sured before commencement of preop-CRT could not discriminate recurrence-free survival
(p = 0.07) among 984 patients who underwent preop-CRT.[28] Portale and coworker recently
demonstrated that neither PLR nor NLR were associated with survival and recurrence in
patients undergoing laparoscopic curative resection for rectal cancer with or without preop-
CRT.[29] The basis of this discrepancy among studies is not clearly understood.
The long course of preop-CRT for locally advanced rectal cancer patients usually takes 11–
15 weeks from preop-CRT commencement to the date of definite surgery. As has been recently
suggested, neutrophil and lymphocyte counts are not constant over time during preop-CRT
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for rectal cancer.[30] So, the NLR will vary in value. Most previous studies evaluating the
impact of NLR on survival or tumor response for rectal cancer measured NLR at a specific
time, mainly before initiating preop-CRT, or used the NLR value assessed before preop-CRT.
[16–20,23–29,31] In contrast, the prognostic significance of change in NLR during preop-CRT
for rectal cancer has not been widely assessed.[32]
Our study aimed to investigate the impact of changes in pre- and post-chemoradiotherapy
neutrophil-to-lymphocyte ratios (NLRs) on the prognosis of patients with rectal cancer who
underwent preop-CRT.
Materials and methods
A retrospective cohort study was conducted using consecutive patients with non-metastatic
rectal cancer who underwent preop-CRT followed by surgery from Jan 2004 to Dec 2013. All
patients diagnosed with clinical stage II or III rectal cancer who underwent long-course preop-
CRT were screened. Patients who underwent emergent or palliative surgeries, were diagnosed
as stage IV at initial staging workup, with history of inflammatory bowel disease, or with any
missing blood examination data during preop-CRT were excluded from this study. Finally,
131 patients were included in this analysis.
Routine demographic variables, surgical outcomes, and oncologic outcomes were obtained
from the electronic medical records, including age, sex, body mass index (BMI), carcinoem-
bryonic antigen (CEA), neutrophil, lymphocyte, monocyte and platelet counts, type of surgery,
hospital stay, recurrence, and survival. NLR was defined by dividing absolute neutrophil count
by absolute lymphocyte count and was calculated twice for each patient using the complete
blood count (CBC) performed before CRT (pre-NLR) and between completion of CRT and
surgery (post-NLR). Additional blood test between these two examinations was not routinely
performed. This study was approved by Gangnam Severance Hospital’s Institutional Review
Board. Informed consent was waived for this retrospective study.
Preoperative chemoradiotherapy, total mesorectal excision and follow up
All patients underwent conventional radiotherapy (RT) with concurrent 5-fluorouracil-based
chemotherapy. Mean 50.4 Gy radiation dose was irradiated in 28 fractions over 5 weeks. RT
was applied to the whole pelvis with 45 Gy in 25 fractions, with a boost of 5.4 Gy to the primary
tumor in 3 fractions. Patients were treated with 3 portals of posterior and bilateral beams in
the prone position. The superior border was 1.5 cm above the sacral promontory (L5 level),
and the inferior border was at the inferior margin of the obturator foramen or 3 cm below the
lower tumor margin. The lateral border was 1.5 cm lateral to the bony pelvis, and the anterior
border was 3 cm anterior to the tumor. The posterior border was 0.5 cm posterior to the sacral
surface. The boost volume was 3 cm expansion from the primary tumor in the superior and
inferior directions and 2 cm expansion radially. Chemotherapy regimens were either intrave-
nous 5-fluorouracil (5-FU) or oral capecitabine. Intravenous chemotherapy was administered
at a dose of 425 mg/m2/day of 5-FU with 20 mg/m2/day of leucovorin during the first and fifth
weeks of radiation treatment (RT). Oral capecitabine was administered at a dose of 1,650 mg/
m2/day during the whole RT period. Surgery was performed in accordance with the principle
of total mesorectal excision (TME) at 6 to 12 weeks after completion of preop-CRT. After sur-
gery, patients were followed up in an out-patient clinic every 3 months for the first 3 years and
3–6 months thereafter until 5 years from the initial surgery. CEA was assessed at each visit.
Chest and abdominopelvic computed tomography (CT) was performed every 6 or 12 months
according to postoperative stage. Colonoscopy was recommended at 1, 3, and 5 years after
surgery. Positron-emission tomography scan or magnetic resonance imaging was added
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according to physician discretion. Local and distant metastases were defined according to clin-
ical and radiologic evaluations. Biopsy confirmation was not always mandatory to confirm
recurrence.
Classifications according to NLRs measured at two different time points
during preoperative chemoradiotherapy
To assess the significance of the change in NLRs while receiving preop-CRT, patients were
stratified into 4 groups using the cut-off value of 3 for both pre-NLR and post-NLR. This cut-
off value was derived from previous studies on the impact of NLR for patients with colorectal
cancer.[33–35] In brief, patients were grouped as follows: group A, pre-NLR < 3 & post-
NLR< 3; group B, pre-NLR < 3 & post-NLR� 3; group C, pre-NLR� 3 & post-NLR < 3;
group D, pre-NLR� 3 & post-NLR� 3. Patients were further sub-stratified as group A versus
groups B-D based on survival outcomes in further analysis.
Propensity score matching
After sub-stratifying the entire cohort into group A versus groups B-D, significant difference
in clinical T stage and marginal difference in clinical N stage was identified between the two
groups, which might affect long-term oncologic outcomes. The following covariates were
included in the model to calculate the propensity score: clinical T stage and clinical N stage.
The NLR dichotomization (group A vs. control) was entered into the regression model as the
dependent variable. Matching of propensity scores was obtained with the 1:1 optimal matching
method.
Further analysis of the impact of neutrophils, lymphocytes, PLR and LMR
on DFS and OS
Using the cohort after propensity score matching, we further evaluated the significance of neu-
trophil, lymphocyte, PLR and LMR with DFS and OS. PLR was defined as the absolute platelet
count divided by the absolute lymphocyte count. LMR was defined as the absolute lymphocyte
count divided by the absolute monocyte count. First, patients were stratified into the 2 groups
using the cut-off value of median for neutrophils, lymphocytes, PLR and LMR respectively.
Second, patients were separately into four grouped as follows: pre-< median & post-<
median; pre-< median & post-�median; pre-�median & post- < median; pre-�median
& post-�median. Finally, patients were sub-stratified as pre-< median & post-< median vs.
control in further analysis.
Statistical analysis
Differences in clinicopathologic features between groups were analyzed using the chi-square
test or Fisher’s exact test for categorical variables and with Student’s t-test for continuous vari-
ables. The primary clinical outcomes of interest were OS and DFS. OS duration was defined as
the time from the date of operation to the date of death or last follow-up. DFS duration was
defined as time from the date of operation to the date of recurrence (local recurrence or/and
distant metastasis), death, or last follow-up. Local recurrence-free survival (LRFS) and distant
metastasis-free survival (DMFS) were defined as time from the date of surgery to the occur-
rence of locoregional recurrence or distant metastasis, respectively. The Kaplan–Meier method
was used for survival analysis, and the log-rank test was used to compare survival outcomes
between the groups. Univariable and multivariable analyses were performed using a Cox pro-
portional hazards model. Variables that had significance of p� 0.1 on univariable analysis
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were eligible for inclusion in multivariable analysis. Multivariable models were derived using
forward stepwise selection. A two-sided p < 0.05 was considered statistically significant. Statis-
tical analyses were performed using IBM SPSS version 23.0 (IBM Corp., Armonk, NY, USA)
and R version 3.5.1 (R-project, Institute for Statistics and Mathematics).
Results
Patient characteristics
A total of 131 patients were included in this study. The median follow-up period was 73.3
[interquartile range (IQR) 56.2–98.1)] months. The majority of patients was male (65.6%) and
diagnosed with low rectal tumor (tumor was located below 6 cm from the anal verge) (71.8%).
The median age was 59 (IQR, 51–67) years, and median BMI was 23.3 (IQR, 21.4–24.8) kg/m2.
Median CEA before starting preop-CRT was 4 (IQR, 2–8) ng/mL. In pre-treatment staging
before preop-CRT, there were 19 (14.5%), 67 (51.1%), and 45 (34.4%) cT2, cT3, and cT4,
respectively. Most patients (80.2%) were diagnosed as clinically node positive.
The median values of pre-NLR and post-NLR were 2.25 (IQR, 1.64–3.29) and 3.46 (IQR,
2.57–4.75), respectively (p< 0.01). Median days from measurement of pre-NLR and post-
NLR to the date of surgery were 98 (IQR, 84–109) and 13 (IQR, 7–18) days, respectively. The
proportion of patients with greater than 3 NLR was 29.8% in pre-NLR and 60.3% in post-NLR
(p< 0.001). Combining the cut-off value of 3 in pre- and post-NLRs, 47 (35.9%), 45 (34.4%), 5
(3.8%), and 34 (26%) patients were classified into group A, group B, group C, and group D,
respectively (Table 1).
Overall survival, disease-free survival, local recurrence-free survival, and
distant metastasis-free survival among 131 patients
Of the 131 patients, local recurrence was observed in 6 (4.5%) and distant metastasis occurred
in 30 (22.9%) during the study period. Overall, death occurred in 38 patients (29%). The
5-year OS and DFS rates were 80.1% and 73.6%, respectively, for all patients. The 5-year LRFS
and DMFS were 95.3% and 78%, respectively, for all patients.
When survival outcomes were compared according to the cut-off value of 3 in pre-NLR,
OS and DFS did not differ between the pre-NLR < 3 and pre-NLR� 3 groups (OS: p = 0.76,
DFS: p = 0.15). At a cut-off value of 3 for post-NLR, there was no difference of OS (p = 0.36)
between the post-NLR < 3 and post-NLR� 3 groups. There was a trend toward better DFS in
the post-NLR < 3 group compared with the post-NLR� 3 group (p = 0.05) (Fig 1A–1D).
Next, OS and DFS were compared among the 4 groups (groups A-D). There was no signifi-
cant difference in 5-year OS or 5-year DFS among the four groups (OS: 82.7% in group A, 80%
in group B, 60% in group C, and 79.4% in group D, p = 0.620, DFS: 84.7% in group A, 65.9%
in group B, 60% in group C, and 70.6% in group D, p = 0.125) (Fig 2A and 2B). When patients
were further sub-stratified into group A versus groups B-D, there was no significant difference
in 5-year OS between the two groups (82.7% in group A vs. 78.6% in groups B-D, p = 0.245).
In contrast, the 5-year DFS rate was significantly better in group A than in groups B-D (84.7%
in group A vs. 67.5% in groups B-D, p = 0.021) (Fig 2C and 2D).
Propensity score matching
The patient characteristics of group A versus groups B-D are described in Table 2. Among 131
patients (before PSM), a significantly higher proportion in groups B-D had advanced clinical
T stage (p = 0.008). Although it was not statistically significant, clinically node positive patients
were more predominant in groups B-D compared to group A (84.5% vs. 72.3%, p = 0.112).
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Because this imbalance of preoperative clinical staging could impact survival outcomes, PSM
with the 1:1 matching method was performed using clinical T and N stages. After matching,
there was no difference in clinicopathologic variables between the two groups.
Univariable and multivariable analyses for DFS after PSM
Using the selected cohort after PSM (n = 94), univariable and multivariable analyses were per-
formed for DFS. In univariable analysis, pre-CRT CEA, tumor distance from the anal verge,
tumor size, ypT, ypN, and combination of pre- and post-NLRs were identified as significant
risk factors for DFS. In multivariable analysis, ypT3-4 vs. ypT0-2 [Hazard Ratio (HR) 2.42,
95% confidence interval (CI) 1–5.8, p = 0.048], yp node positive vs. yp node negative (HR 5.6,
95% CI 2.43–12.93, p< 0.001), and pre-NLR<3 & post-NLR<3 vs. control (HR 0.37, 95% CI
0.15–0.92, p = 0.033) remained as independent prognostic factors for DFS (Table 3).
Correlations of neutrophil, lymphocytes, PLR and LMR with DFS and OS
The pre- and post- median values of the neutrophil, lymphocytes, PLR and LMR were shown
in S1 Table. Using the median values as the cut-off points, prognostic impact of each variable
was investigated. There was no survival difference according to neutrophil, lymphocyte, PLR,
and LMR either evaluated in pre- and post- measurements (S2 Table). When we classified
patients into the four groups using combination of pre- and post- PLRs and LMRs respectively,
Table 1. Clinicopathologic characteristics of overall patients (n = 131).
N (%)
Gender Male 86 (65.6)
Female 45 (34.4)
Age (years) median (IQRa) 59 (51–67)
BMIb (kg/m2) median (IQR) 23.3 (21.4–24.8)
Tumor distance from anal verge (cm) < 6 94 (71.8)
� 6 37 (28.2)
Pre-CRT CEAc (ng/mL) median (IQR) 4 (2–8)
cT stage cT2 19 (14.5)
cT3 67 (51.1)
cT4 45 (34.4)
cN stage cN (–) 26 (19.8)
cN (+) 105 (80.2)
pre-NLR median (IQR) 2.25 (1.64–3.29)
< 3 92 (70.2)
� 3 39 (29.8)
post-NLR median (IQR) 3.46 (2.57–4.75)
< 3 52 (39.7)
� 3 79 (60.3)
Combination of pre&post NLRs pre-NLR<3 & post-NLR<3 (Group A) 47 (35.9)
pre-NLR<3 & post-NLR�3 (Group B) 45 (34.4)
pre-NLR�3 & post-NLR<3 (Group C) 5 (3.8)
pre-NLR�3 & post-NLR�3 (Group D) 34 (26)
aIQR: interquartile range
bBMI: body mass index
cCEA: carcinoembryonic antigen
https://doi.org/10.1371/journal.pone.0214415.t001
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Kaplan-Meier plot showed no survival difference between the groups (S1 Fig, Fig 1A–1D).
Even when we re-classified those four groups into the two groups, such as pre-PLR<154.4 &
post-PLR<255.7 vs. control or pre-LMR<5.42 & post-LMR<3.15 vs. control, there was no
survival difference between the two groups. When the patients were dichotomized as pre-
Fig 1. Overall survival and disease-free survival according to cut-off value 3 of pre-NLR (A, B) and post-NLR (C, D).
https://doi.org/10.1371/journal.pone.0214415.g001
Fig 2. Overall survival and disease-free survival according to combination of pre and post NLRs using cut-off value 3 (A, B) and
according to group A versus groups B-D (C, D) in whole cohort (n = 131).
https://doi.org/10.1371/journal.pone.0214415.g002
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Table 2. Patients’ characteristics according to combination of pre and post-chemoradiotherapy neutrophil-to-lymphocyte ratio before and after propensity score
matching (PSM).
Unmatched patients (n = 131) Matched patients (n = 94)
Group A (n = 47)
n (%)
Group B-D (n = 84)
n (%)
P Group A (n = 47)
n (%)
Control (n = 47)
n (%)
P
Gender Male 28 (59.6) 58 (69) 0.338 28 (59.6) 33 (70.2) 0.388
Female 19 (40.4) 26 (31) 19 (40.4) 14 (29.8)
Age (years) < 65 31 (66) 62 (73.8) 0.423 31 (66) 35 (74.5) 0.499
� 65 16 (34) 22 (26.2) 16 (34) 12 (25.5)
BMIa (kg/m2) < 25 34 (72.3) 68 (81) 0.278 34 (72.3) 35 (74.5) 1.0
� 25 13 (27.7) 16 (19) 13 (27.7) 12 (25.5)
Tumor distance from anal verge (cm) < 6 40 (85.1) 54 (64.3) 0.015 40 (85.1) 38 (80.9) 0.785
� 6 7 (14.9) 30 (35.7) 7 (14.9) 9 (19.1)
Pre-CRT CEA
b
(ng/mL) < 5 33 (70.2) 48 (57.1) 0.189 33 (70.2) 28 (59.6) 0.388
� 5 14 (29.8) 36 (42.9) 14 (29.8) 19 (40.4)
cT stagec cT2 11 (23.4) 8 (9.5) 0.008 11 (23.4) 8 (17) 0.772
cT3 27 (57.4) 40 (47.6) 27 (57.4) 30 (63.8)
cT4 9 (19.1) 36 (42.9) 9 (19.1) 9 (19.1)
cN stagec cN (–) 13 (27.7) 13 (15.5) 0.112 13 (27.7) 10 (21.3) 0.632
cN (+) 34 (72.3) 71 (84.5) 34 (72.3) 37 (78.7)
Operation method LARd 25 (53.2) 43 (51.2) 0.890 25 (53.2) 17 (36.2) 0.241e
CAAf /ISRg 19 (40.4) 33 (39.3) 19 (40.4) 25 (53.2)
APR
h
/Hartmann 3 (6.4) 8 (9.5) 3 (6.4) 5 (10.6)
Complications Yes 16 (34) 31 (36.9) 0.850 16 (34) 15 (31.9) 1.0
No 31 (66) 32 (68.1) 31 (66) 32 (68.1)
Anastomotic leakage
i
Yes 1 (2.3) 4 (5.3) 0.651 1 (2.3) 0 1.0
No 43 (97.7) 72 (94.7) 43 (97.7) 42 (100)
Tumor size (cm) < 5 47 (100) 71 (93.4) 0.157e 47 (100) 45 (95.7) 0.495e
� 5 0 5 (6.6) 0 2 (4.3)
ypT ypT0-2 31 (66) 35 (41.7) 0.011 31 (66) 23 (48.9) 0.144
ypT3-4 16 (34) 49 (58.3) 16 (34) 24 (51.1)
ypN Negative 38 (80.9) 57 (67.9) 0.153 38 (80.9) 36 (76.6) 0.802
Positive 9 (19.1) 27 (32.1) 9 (19.1) 11 (23.4)
pCRj Yes 10 (21.3) 12 (14.3) 0.336 10 (21.3) 7 (14.9) 0.593
No 37 (78.7) 72 (85.7) 37 (78.7) 40 (85.1)
CRM
k
Positive (� 1 mm) 1 (2.1) 3 (3.9) 0.834
e
1 (2.1) 2 (4.3) 0.164
e
Negative (> 1 mm) 17 (36.2) 31 (40.8) 17 (36.2) 9 (19.1)
missing 29 (61.7) 42 (55.3) 29 (61.7) 36 (76.6)
Postoperative chemotherapy None 8 (17) 11 (13.1) 0.519
e
8 (17) 4 (8.5) 0.587
e
IV 5FUl / Oral 5FU 37 (78.7) 65 (77.4) 37 (78.7) 40 (85.1)
FOLFOXm / FOLFIRIn 2 (4.3) 8 (9.5) 2 (4.3) 3 (6.4)
aBMI: body mass index
bCEA: carcinoembryonic antigen
c: Matched variables
dLAR: low anterior resection
e: Fisher’s exact test
fCAA: coloanal anastomosis
gISR: intersphincteric resection
hAPR: abdominoperineal resection
i: Of the 120 and 86 patients respectively who underwent sphincter preserving procedures (low anterior resection or coloanal anastomosis/intersphincteric resection)
jpCR: pathologic complete response
kCRM: circumferential resection margin
lFU: 5-fluorouracil/leucovorin
mFOLFOX: folinic acid, 5-fluorouracil, oxaliplatin
nFOLFIRI: folinic acid, 5-fluorouracil, irinotecan
https://doi.org/10.1371/journal.pone.0214415.t002
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Table 3. Univariable and multivariable Cox-regression analysis for DFS after PSM (n = 94).
Univariable analysis Multivariable analysis
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Gender Male 1
Female 0.9 (0.38–2.11) 0.820
Age (years) < 65 1
� 65 1 (0.43–2.51) 0.925
BMIa (kg/m2) < 25 1
� 25 0.67 (0.25–1.81) 0.437
cT stage cT2 1
cT3 2.82 (0.64–12.27) 0.167
cT4 3.89 (0.78–19.28) 0.096
cN stage cN (–) 1
cN (+) 4.05 (0.95–17.23) 0.058
Pre-CRT CEAb (ng/mL) < 5 1
� 5 2.3 (1.0–5.14) 0.042
Tumor distance from anal verge (cm) < 6 1
� 6 2.49 (1.03–6.04) 0.042
Operation name LARc 1
CAAd & ISRe 0.55 (0.22–1.32) 0.185
APRf & Hartmann 1.26 (0.36–4.43) 0.715
Operation time (min) < 360 1
� 360 1.31 (0.49–3.53) 0.582
Tumor size (cm) < 5 1
� 5 5.28 (1.23–22.7) 0.025
ypT ypT0-2 1 1
ypT3-4 3.26 (1.39–7.63) 0.006 2.42 (1–5.8) 0.048
ypN Negative 1 1
Positive 5.88 (2.62–13.19) <0.001 5.6 (2.43–12.93) <0.001
CRMg Positive (� 1 mm) 1
Negative (> 1mm) 1.39 (0.18–10.7) 0.746
missing 1.31 (0.17–9.76) 0.792
Complications No 1
Yes 2.05 (0.92–4.6) 0.079
pre-NLR < 3 1
�3 2.01 (0.86–4.7) 0.107
post-NLR < 3 1
�3 2.08 (0.91–4.77) 0.081
Combination of pre&post NLRs Control 1 1
pre-NLR<3 & post-NLR<3 0.37 (0.15–0.89) 0.027 0.37 (0.15–0.92) 0.033
aBMI: body mass index
bCEA: carcinoembryonic antigen
cLAR: low anterior resection
dCAA: coloanal anastomosis
eISR: intersphincteric resection
fAPR: abdominoperineal resection
gCRM: circumferential resection margin
https://doi.org/10.1371/journal.pone.0214415.t003
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LMR�5.42 & post-LMR�3.15 vs. control, there was no survival difference between the two
groups (S3 Table).
Discussion
This study demonstrated that persistent non-inflammatory status during preop-CRT, assessed
by a combination of neutrophil-to-lymphocyte ratios obtained at two different time points,
might be associated with low possibility of recurrence in patients with locally advanced non-
metastatic rectal cancer who underwent long course preop-CRT followed by surgery.
Previous meta-analysis on the prognostic effect of NLR in patients with rectal cancer
showed that elevated NLR was associated with poor survival, with HRs of 13.4 in OS, 4.3 in
DFS, and 3.6 in relapse free survival.[22] Nevertheless, several recent studies reported that
NLR could not discriminate prognosis in patients with non-metastatic rectal cancer with or
without preop-CRT.[26–29] The different impacts of NLR may, to some extent, be explained
by weakened predictive power of the NLR due to the narrow spectrum of tumor burden, ran-
dom error caused by small sample size, or racial differences.[27,29] However, the exact reason
for this discrepancy was not clearly depicted. In our study, there was no difference in OS or
DFS according to the cut-off value of 3 for pre-NLR. Although DFS was marginally lower in
patients with post-NLR > 3, the significance was not sustained in multivariable analysis after
propensity score matching. Considering only these results, our study was in line with previous
studies reporting the irrelevance of NLR with long-term prognosis in patients with rectal can-
cer who underwent preop-CRT. However, after combining consecutive values of NLRs during
preop-CRT, our cohort can be separated into two distinct groups showing different survival
outcomes.
As far as we know, only one study has reported the clinical usefulness of combining pre-
and post-NLRs to predict survival outcomes in patients with locally advanced rectal cancer
who underwent preop-CRT. Sung and colleagues reported that persistently elevated NLRs
measured twice during preop-CRT, in comparison to the persistently lower group, showed
poor DFS (HR: 4.35, 95% CI: 1.361–13.901, p = 0.013).[32] It should be mentioned that those
authors divided their groups using the cut-off points of 1.75 in pre-CRT NLR and 5.14 in post-
CRT NLR, as these values were determined to maximize the log-rank test of survival. However,
the cut-off value of 1.75 was relatively lower than that used in previous studies, and most
patients (72.5%) were allocated into the high pre-CRT NLR group (Table 4). According to the
recent analysis of 12,160 healthy Korean people, the mean ± 1.96 standard deviation of NLR
was reported to be 1.65 (0.107–3.193).[36] In addition, mean (95% CI) NLR was reported as
2.15 (2.11–2.19) using 9,427 subjects participating in the National Health and Nutritional
Examination Survey in the USA.[37] As those authors already stated, more supporting data
are required to accept those cut-off values in clinical practice.
Although various studies showed the prognostic impact of NLR on survival, there was no
consensus for cut-off values of NLR in patients with colorectal cancer. Some authors used an
ROC curve to define the optimal cut-off value in which the variable of interest was death or
pathologic tumor response.[16,19,25] Other studies decided on a point that could maximize
survival differences.[21,28,32] Our cut-off value 3 was also arbitrary and was based on what
had been studied or suggested in previous studies on colorectal cancers.[33–35] Nevertheless,
the discriminative power of our cut-off value was well demonstrated in various patients with
colorectal cancer irrespective of race, which makes our findings more generalizable.
When we divided our cohort into the persistently lower NLR group (group A) versus
groups B-D, there was an uneven distribution of baseline characteristics, especially for clinical
staging. The persistently lower NLR group (group A) was associated with earlier clinical T
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Table 4. Results of previous studies on NLR in rectal cancer patients with or without preoperative chemoradiotherapy.
Authors year/
nation
No. of
patients
(% of
CRT)
Measurement Neutrophil to lymphocyte
ratio (NLR)
Correlations
Median
(range)
Cut-
off
High
NLR
Long term survival outcomes Pathologic tumor response
Carruthers
et al.[17]
2012/UK 115 (100) Before CRT N/A 5.0 N/A Correlation: (+) Low NLR vs.
High NLR:
OS—HR 7.0, 95% CI (2.6–19.2),
p = 0.006
DFS—HR 4.1, 95% CI (1.7–9.8),
p = 0.03
Not evaluated
Krauthamer
et al.[23]
2013/
Israel
71 (100) Before CRT N/A 5.0 35.2% Not evaluated Correlation: (+) High NLR vs. Low
NLR:
pCR—OR 2.54, 95% CI (1.52–4.18),
p = 0.04 (Only in clinical stage III
patients, multivariable analysis)
Shen L et al.
[16]
2014/
China
199 (100) Before CRT 2.4 (1.0–8.9) 2.8 33.2% Correlation: (+) Low NLR vs.
High NLR:
OS—HR 2.123, 95% CI (1.14–
3.954), p = 0.018
DFS—HR 1.363, 95% CI (0.840–
2.214), p = 0.210
Correlation: (-) mean NLR of TRG 0–1
vs. TRG 2–3: 2.68 ± 1.42 vs. 2.82 ± 1.33,
p = 0.873
Kim IY et al.
[18]
2014/
Korea
102 (100) Before CRT N/A 3.0 24.5% Correlation: (+) Low NLR vs.
High NLR:
Cancer specific survival—HR
6.6, 95% CI (1.3–32), p = 0.02
Recurrence free survival—HR
2.8, 95% CI (1.1–6.8), p = 0.03
Correlation: (+) Low NLR vs. High
NLR:
poor pathologic tumor response
(ypTNM II-IV)—OR 5.2, 95% CI (1.1–
26.5), p = 0.04
After CRT N/A 3.0 49% Not evaluated Correlation: (-) Low NLR vs. High
NLR:
poor pathologic tumor response
(ypTNM II-IV)—p = 0.4
Nagasaki
et al.[19]
2015/
Japan
201(100) Before CRT 2.3 (0.8–11.1) 3.0 21.9% Correlation: (+) Low NLR vs.
High NLR:
OS—HR 3.381, 95% CI (1.307–
8.751), p = 0.012
RFS—No association
Not evaluated
Caputo et al.
[24]
2016/Italy 87 (100) Before CRT 2.4 (0.9–9.8) 2.8 35.6% Not evaluated Correlation: (-) High NLR vs. Low
NLR:
TRG—p = 0.942
After CRT 3.7 (1.3–33.4) 3.8 49.4% Not evaluated Correlation: (+) High NLR:
Higher rates of TRG 4 response—
p = 0.033
Hodek et al.
[31]
2016/
Czech
Republic
173 (100) Before CRT 2.78 (0.64–
14.84)
2.8 49.1% Correlation: (+) Low NLR vs.
High NLR:
OS—p = 0.03
DFS—p = 0.20 (univariable
analysis)
Correlation: (-)
pCR—p = 0.43
Lee et al.[25] 2017/
Korea
291 (100) Before CRT N/A 5.0 9.6% Correlation: (+) Low NLR vs.
High NLR:
Relapse rate—OR 2.4, 95% CI
(1.09–5.27), p = 0.025
(univariable analysis)
Correlation: (+) Low NLR vs. High
NLR:
pCR—15.3% vs. 0%, p = 0.026
(univariable analysis)
After CRT N/A 5.0 27.1% Correlation: (-) No detailed data Correlation: (-) No detailed data
Sung et al.
[32]
2017/
Korea
110 (100) Before CRT 2.1 (0.53–
10.63)
1.75 72.7% Correlation: (+) Pre-NLR�1.75 &
Post-NLR�5.14 vs. Pre-
NLR>1.75 & Post-NLR>5.14:
DFS—HR 4.350, 95% CI (1.361–
13.901), p = 0.013
Correlation: (-) Pre-NLR�1.75 & Post-
NLR�5.14 vs. Pre-NLR>1.75 & Post-
NLR�5.14 or Pre-NLR�1.75 & Post-
NLR>5.14 vs. Pre-NLR>1.75 & Post-
NLR>5.14: pCR—6.9% vs. 13.1% vs.
5%, p = 0.467
After CRT 3.23 (0.48–
21.64)
5.14 19%
(Continued)
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staging. Association of high NLR with advanced staging was also observed in other studies.
Shen and colleagues reported a significantly higher clinical stage III rate in the high NLR
group (95.4%) compared to that of the low NLR group (82.7%) (p = 0.012).[16] In another
large-scale study evaluating various blood-derived immune parameters, patients in the high
NLR group, which was defined as> 1.7 NLR, had more advanced ypT stage and ypN1 stage.
[28] Based on these observations, we cannot exclude the possibility that NLR is a biomarker
reflecting an advanced stage. Although the inherent skewness of clinical staging might trans-
late into favorable or poor survival outcomes, we tried to balance clinical staging between the
comparative groups using propensity score matching. One strength of this study is the effort
to reduce selection bias.
Table 4. (Continued)
Authors year/
nation
No. of
patients
(% of
CRT)
Measurement Neutrophil to lymphocyte
ratio (NLR)
Correlations
Median
(range)
Cut-
off
High
NLR
Long term survival outcomes Pathologic tumor response
Kim TG et al.
[20]
2018/
Korea
176 (100) Before CRT N/A 2.0 51.7% Correlation: (+) Low NLR vs.
High NLR:
OS—92.4% vs. 71.9%, p = 0.027
DFS—86.8% vs. 70.7%, p = 0.014
(multivariable analysis)
Correlation: (+) Low NLR vs. High
NLR:
Poor tumor response (Dworak grade
0–2)—OR 2.49, 95% CI (1.264–4.904),
p = 0.008 (multivariable analysis)
Vallard et al.
[21]
2018/
France
257(100) Before CRT N/A 2.8 27.6% Correlation: (+) Low NLR vs.
High NLR:
Local recurrence—OR 14.7, 95%
CI (1.53–334.3), p = 0.03
Progression-free survival—HR
2.21, 95% CI (1.26–3.86),
p = 0.006
Overall survival—HR 2.23, 95%
CI (1.14–2.36), p = 0.02
Correlation: (-) Low NLR vs. High
NLR:
Good pathologic response (Mandard
grade 1–2)-OR 0.53, 95% CI (0.26–
1.02), p = 0.06
After CRT N/A 2.5 N/A Correlation: (-) Correlation: (-)
Lino-Silva
et al.[26]
2016/
Mexico
175 (100) Before CRT 2.65 ± 1.32�
(0.58–6.89)
3.0 17.7% Correlation: (-) Low NLR vs.
High NLR:
OS—77.6% vs. 75.9%, p = 0.548
Correlation: (-) Low NLR vs. High
NLR:
pCR—no difference
Shen J et al.
[27]
2017/
China
202 (100) Before CRT 2.4 (0.6–12.8) 3.0 31.2% Correlation: (-) Low NLR vs.
High NLR:
OS—HR 1.066, 95% CI (0.681–
1.668), p = 0.779
DFS—HR 0.863, 95% CI (0.536–
1.390), p = 0.542
Correlation: (-) Low NLR vs. High
NLR:
Good pathologic response (Dworak
grade 3–4) - 56.8% vs. 63.4%, p = 0.359
Jung et al.[28] 2017/
Korea
984 (100) Before CRT N/A 1.7 55.5% Correlation: (-) Low NLR vs.
High NLR:
Recurrence free survival—HR
1.319, 95% CI(0.978–5.087),
p = 0.07
Correlation: (-) TRG—p = 0.25
Portale et al.
[29]
2018/Italy 152
(32.2)
Before CRT or
surgery
2.2 (IQR, 1.7–
3.1)
N/A N/A Correlation: (-) NLR—Poor
discriminative performance:
OS—AUC 0.47 DFS—AUC 0.47
Not evaluated
This study Korea 131 (100) Before CRT 2.25 (IQR,
1.64–3.29)
3.0 29.8% Correlation: (+) Control vs. pre-
NLR< 3 & post-NLR< 3:
DFS—HR 0.37, 95% CI (0.15–
0.92), p = 0.033
Correlation: (-) pre-NLR< 3 & post-
NLR < 3 vs. control: pCR—21.3% vs.
14.9%, p = 0.593After CRT 3.46 (IQR,
2.57–4.75)
3.0 60.3%
Abbreviations: OS: Overall survival, DFS: Disease-free survival, RFS: Relapse free survival, pCR: pathologic complete response, TRG: Tumor regression grade N/A: Not
available
�: Mean ± SD, IQR: interquartile range
https://doi.org/10.1371/journal.pone.0214415.t004
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When NLR values measured before starting preop-CRT and after completion of preop-
CRT in previous studies were compared (Table 4), the median NLR value measured after com-
pletion of CRT is relatively higher than that measured before initiation of CRT (2.4!3.7 in
Caputo et al., 2.1!3.23 in Sung et al. respectively).[24,32] In the same sense, some studies
reported that the rate of high NLR increased after completion of CRT (24.5%!49% in Kim IY
et al., 9.6%! 27.1% in Lee et al. respectively).[18,25] This phenomenon was also observed in
our study. Lee and colleagues reported that neutrophil and lymphocyte counts were maximally
decreased 2 weeks after CRT onset in patients with rectal cancer.[30] The neutrophil count
increased slightly until the date of surgery; however, the lymphocyte count further decreased
until 1 month after commencing preop-CRT. Similarly, Kitayama and colleagues reported that
the numbers of neutrophils and monocytes were comparably maintained, while circulating
lymphocytes were most markedly decreased during CRT for patients with rectal cancer.[38]
Based on these observations, it seems reasonable to assume that decreased peripheral lympho-
cytes may be one of the major reasons for increased NLR value after completion of preop-
CRT. Lymphocytes are the most radio-sensitive cells, and lymphocyte LD50 (lethal dose 50) is
among the lowest in the body.[39,40] Reasons for depletion of peripheral lymphocyte after
radiation therapy have been suggested as direct irradiation of circulating lymphocytes and/or
bone marrow suppression, although the causes of this hematologic response are diverse and
remain unknown for rectal cancer.[41]
The physiologic role of lymphocytes is to suppress tumor progression via cytotoxic cell
death and cancer immune surveillance.[42] The association of radiation-induced lymphopenia
with poor survival has been reported in various solid tumors including brain tumors, head and
neck cancer, lung cancer, esophageal cancer, breast cancer, pancreatic cancer, and cervical
cancer.[41] The clinical impact of lymphocyte count during preop-CRT in patients with rectal
cancer was investigated to show that sustaining lymphocyte ratio� 0.35 at 4 weeks after com-
mencement of CRT, which was defined as lymphocyte count at 4 weeks divided by baseline
lymphocyte count, was an independent predictor of pCR.[43] However, the host response on
depletion and/or recovery of circulating lymphocytes during radiation therapy might be differ-
ent. In our group, among patients who showed pre-NLR <3, 48.9% of patients were catego-
rized into the>3 post-NLR group, while 51.1% of patients stayed in the<3 post-NLR group.
The current study could not definitively explain why this kind of hematologic response was
different among patients, although the explanation is likely multifactorial. In brief, our results
suggest that the preserved host immunity identified during the preop-CRT period can be
retained as a long-term effect for patients with rectal cancer, although further studies are
needed to validate our findings.
As part of further analyses, we evaluated that the number of neutrophil, lymphocytes, PLR
and LMR had some prognostic impact. When we dichotomized our patients into the two sepa-
rate groups using the median value of pre- and post- measurements, there was no survival dif-
ference between the two groups (S1 and S2 Tables). These trends lasted when we sub-divided
patients in more detail (S1A–S1D Fig, S3 Table). Some previous studies demonstrated that
PLR or LMR had prognostic power in rectal cancer patients who underwent preop-CRT.
[28,44–47] Nevertheless, there were some contradictory results[20,48,49] and the cut-off
points were heterogeneous among the studies.[44–47] Although our study did not reveal any
association between PLR and LMR with survival outcomes, the small sample size of our study
and unconfirmed cut-off values might hinder to make a concrete conclusion. It was demon-
strated that NLR, PLR and LMR were basically positively correlated with each other.[28,50]
Thus, comparing the prognostic impact of PLR, LMR or NLR should be thoroughly investi-
gated and discussed with large populations to exclude the possible interaction between these
parameters.
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Some limitations of this study have to be acknowledged. The main limitation is derived
from the retrospective and single center-based study design. Thus, critical postoperative patho-
logic outcomes, such as circumferential resection margin, lymphovascular invasion, and peri-
neural invasion, were not adequately included in final survival analysis. The low specificity
of NLR is an inherent limitation of this design. Various conditions, such as hidden infection
or pharmacologic response, might influence the value of NLR. Although our study tried to
exclude patients with specific conditions such as inflammatory bowel disease-associated rectal
cancer, the inherent retrospective nature of this study could not fully exclude patients who had
undetectable external sources of inflammatory reaction when blood was sampled. Although
the cut-off value used in our study was suggested by previous studies, diverse cut-off values are
used in different studies (Table 4). The racial difference of normal NLR values might make it
more difficult to generate a universal reference.[6,36,37] The lack of consensus on cut-off val-
ues remains a serious problem and hampers clinical utilization of these findings.
In conclusion, our study demonstrated that persistent lower NLRs during preop-CRT is
associated with low possibility of recurrence after surgery in patients with non-metastatic rec-
tal cancer. Considering the debate on the necessity of adjuvant chemotherapy for patients with
rectal cancer after preop-CRT, especially for patients with good tumor response,[51,52] our
observation might be used to stratify patients for additional treatments. Further studies to vali-
date this hypothesis are needed.
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